Korean guidelines for the pharmacological treatment of social anxiety disorder: Initial treatment strategies

Hyungkun Yoon, Dong Jae Oh, Ho Suk Suh, Kyoung Uk Lee, Se Won Lim, Jun Yeob Lee, Jong Chul Yang, Jae Hon Lee, Juwon Ha, Bun Hee Lee, Seung Gul Kang, Ho-Kyoung Yoon, Jihyun Moon, Seung Min Bae, Youngdo Kwon, Hyun Chung Kim, Kang Seob Oh

Research output: Contribution to journalArticle

Abstract

Objective The aim of the present study was to provide clinical consensus and evidence regarding initial treatment strategies for the pharmacological treatment of social anxiety disorder (SAD) in Korea. Methods We prepared a questionnaire to derive a consensus from clinicians regarding their preference for the pharmacological treatment of SAD in Korea. Data regarding medication regimens and psychotropic drugs used during initial treatment, the doses used, and the pharmacological treatment duration were obtained. Responses were obtained from 66 SAD experts, and their opinions were classified into three categories (first-line, second-line, third-line) using a chi-square analysis. Results Clinicians agreed upon first-line regimens for SAD involving monotherapy with selective serotonin reuptake inhibitors (SS-RIs) or the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine, or combined therapy using antidepressants with beta-blockers or benzodiazepines on a standing or as-needed basis. First-line psychotropic drug choices for initial treatment included the following: escitalopram, paroxetine, sertraline, venlafaxine, and propranolol. The medication dosage used by domestic clinicians was found to be comparable with foreign guidelines. Domestic clinicians tended to make treatment decisions in a shorter amount of time and preferred a similar duration of maintenance treatment for SAD when compared with foreign clinicians. Conclusion This study may provide significant information for developing SAD pharmacotherapy guidelines in Korea, especially in the early stage of treatment.

Original languageEnglish
Pages (from-to)147-155
Number of pages9
JournalPsychiatry Investigation
Volume15
Issue number2
DOIs
Publication statusPublished - 2018 Feb 1

Fingerprint

Pharmacology
Guidelines
Korea
Therapeutics
Psychotropic Drugs
Consensus
Social Phobia
Sertraline
Paroxetine
Citalopram
Serotonin Uptake Inhibitors
Expert Testimony
Benzodiazepines
Propranolol
Antidepressive Agents
Drug Therapy

Keywords

  • Anxiety disorder
  • Guideline
  • Initial treatment
  • Pharmacotherapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Korean guidelines for the pharmacological treatment of social anxiety disorder : Initial treatment strategies. / Yoon, Hyungkun; Oh, Dong Jae; Suh, Ho Suk; Lee, Kyoung Uk; Lim, Se Won; Lee, Jun Yeob; Yang, Jong Chul; Lee, Jae Hon; Ha, Juwon; Lee, Bun Hee; Kang, Seung Gul; Yoon, Ho-Kyoung; Moon, Jihyun; Bae, Seung Min; Kwon, Youngdo; Kim, Hyun Chung; Oh, Kang Seob.

In: Psychiatry Investigation, Vol. 15, No. 2, 01.02.2018, p. 147-155.

Research output: Contribution to journalArticle

Yoon, H, Oh, DJ, Suh, HS, Lee, KU, Lim, SW, Lee, JY, Yang, JC, Lee, JH, Ha, J, Lee, BH, Kang, SG, Yoon, H-K, Moon, J, Bae, SM, Kwon, Y, Kim, HC & Oh, KS 2018, 'Korean guidelines for the pharmacological treatment of social anxiety disorder: Initial treatment strategies', Psychiatry Investigation, vol. 15, no. 2, pp. 147-155. https://doi.org/10.30773/pi.2017.05.01
Yoon, Hyungkun ; Oh, Dong Jae ; Suh, Ho Suk ; Lee, Kyoung Uk ; Lim, Se Won ; Lee, Jun Yeob ; Yang, Jong Chul ; Lee, Jae Hon ; Ha, Juwon ; Lee, Bun Hee ; Kang, Seung Gul ; Yoon, Ho-Kyoung ; Moon, Jihyun ; Bae, Seung Min ; Kwon, Youngdo ; Kim, Hyun Chung ; Oh, Kang Seob. / Korean guidelines for the pharmacological treatment of social anxiety disorder : Initial treatment strategies. In: Psychiatry Investigation. 2018 ; Vol. 15, No. 2. pp. 147-155.
@article{dc9b29f7a04149fdb8d1e926e735a23c,
title = "Korean guidelines for the pharmacological treatment of social anxiety disorder: Initial treatment strategies",
abstract = "Objective The aim of the present study was to provide clinical consensus and evidence regarding initial treatment strategies for the pharmacological treatment of social anxiety disorder (SAD) in Korea. Methods We prepared a questionnaire to derive a consensus from clinicians regarding their preference for the pharmacological treatment of SAD in Korea. Data regarding medication regimens and psychotropic drugs used during initial treatment, the doses used, and the pharmacological treatment duration were obtained. Responses were obtained from 66 SAD experts, and their opinions were classified into three categories (first-line, second-line, third-line) using a chi-square analysis. Results Clinicians agreed upon first-line regimens for SAD involving monotherapy with selective serotonin reuptake inhibitors (SS-RIs) or the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine, or combined therapy using antidepressants with beta-blockers or benzodiazepines on a standing or as-needed basis. First-line psychotropic drug choices for initial treatment included the following: escitalopram, paroxetine, sertraline, venlafaxine, and propranolol. The medication dosage used by domestic clinicians was found to be comparable with foreign guidelines. Domestic clinicians tended to make treatment decisions in a shorter amount of time and preferred a similar duration of maintenance treatment for SAD when compared with foreign clinicians. Conclusion This study may provide significant information for developing SAD pharmacotherapy guidelines in Korea, especially in the early stage of treatment.",
keywords = "Anxiety disorder, Guideline, Initial treatment, Pharmacotherapy",
author = "Hyungkun Yoon and Oh, {Dong Jae} and Suh, {Ho Suk} and Lee, {Kyoung Uk} and Lim, {Se Won} and Lee, {Jun Yeob} and Yang, {Jong Chul} and Lee, {Jae Hon} and Juwon Ha and Lee, {Bun Hee} and Kang, {Seung Gul} and Ho-Kyoung Yoon and Jihyun Moon and Bae, {Seung Min} and Youngdo Kwon and Kim, {Hyun Chung} and Oh, {Kang Seob}",
year = "2018",
month = "2",
day = "1",
doi = "10.30773/pi.2017.05.01",
language = "English",
volume = "15",
pages = "147--155",
journal = "Psychiatry Investigation",
issn = "1738-3684",
publisher = "Korean Neuropsychiatric Association",
number = "2",

}

TY - JOUR

T1 - Korean guidelines for the pharmacological treatment of social anxiety disorder

T2 - Initial treatment strategies

AU - Yoon, Hyungkun

AU - Oh, Dong Jae

AU - Suh, Ho Suk

AU - Lee, Kyoung Uk

AU - Lim, Se Won

AU - Lee, Jun Yeob

AU - Yang, Jong Chul

AU - Lee, Jae Hon

AU - Ha, Juwon

AU - Lee, Bun Hee

AU - Kang, Seung Gul

AU - Yoon, Ho-Kyoung

AU - Moon, Jihyun

AU - Bae, Seung Min

AU - Kwon, Youngdo

AU - Kim, Hyun Chung

AU - Oh, Kang Seob

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Objective The aim of the present study was to provide clinical consensus and evidence regarding initial treatment strategies for the pharmacological treatment of social anxiety disorder (SAD) in Korea. Methods We prepared a questionnaire to derive a consensus from clinicians regarding their preference for the pharmacological treatment of SAD in Korea. Data regarding medication regimens and psychotropic drugs used during initial treatment, the doses used, and the pharmacological treatment duration were obtained. Responses were obtained from 66 SAD experts, and their opinions were classified into three categories (first-line, second-line, third-line) using a chi-square analysis. Results Clinicians agreed upon first-line regimens for SAD involving monotherapy with selective serotonin reuptake inhibitors (SS-RIs) or the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine, or combined therapy using antidepressants with beta-blockers or benzodiazepines on a standing or as-needed basis. First-line psychotropic drug choices for initial treatment included the following: escitalopram, paroxetine, sertraline, venlafaxine, and propranolol. The medication dosage used by domestic clinicians was found to be comparable with foreign guidelines. Domestic clinicians tended to make treatment decisions in a shorter amount of time and preferred a similar duration of maintenance treatment for SAD when compared with foreign clinicians. Conclusion This study may provide significant information for developing SAD pharmacotherapy guidelines in Korea, especially in the early stage of treatment.

AB - Objective The aim of the present study was to provide clinical consensus and evidence regarding initial treatment strategies for the pharmacological treatment of social anxiety disorder (SAD) in Korea. Methods We prepared a questionnaire to derive a consensus from clinicians regarding their preference for the pharmacological treatment of SAD in Korea. Data regarding medication regimens and psychotropic drugs used during initial treatment, the doses used, and the pharmacological treatment duration were obtained. Responses were obtained from 66 SAD experts, and their opinions were classified into three categories (first-line, second-line, third-line) using a chi-square analysis. Results Clinicians agreed upon first-line regimens for SAD involving monotherapy with selective serotonin reuptake inhibitors (SS-RIs) or the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine, or combined therapy using antidepressants with beta-blockers or benzodiazepines on a standing or as-needed basis. First-line psychotropic drug choices for initial treatment included the following: escitalopram, paroxetine, sertraline, venlafaxine, and propranolol. The medication dosage used by domestic clinicians was found to be comparable with foreign guidelines. Domestic clinicians tended to make treatment decisions in a shorter amount of time and preferred a similar duration of maintenance treatment for SAD when compared with foreign clinicians. Conclusion This study may provide significant information for developing SAD pharmacotherapy guidelines in Korea, especially in the early stage of treatment.

KW - Anxiety disorder

KW - Guideline

KW - Initial treatment

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=85042540474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042540474&partnerID=8YFLogxK

U2 - 10.30773/pi.2017.05.01

DO - 10.30773/pi.2017.05.01

M3 - Article

AN - SCOPUS:85042540474

VL - 15

SP - 147

EP - 155

JO - Psychiatry Investigation

JF - Psychiatry Investigation

SN - 1738-3684

IS - 2

ER -